Joint Formulary & PAD

Secukinumab - Psoriasis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Not Specified
Associated Icons :
BNF SPC
ICB
NICE
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Secukinumab
Indication :
Psoriasis
Group Name :
Keywords :
Biologic, NICE, immunosuppressant, interleukin 17A inhibitor, DMARD, bDmard, Disease modulating, Dermatology,
Brand Names Include :
Cosentyx
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Secukinumab is used to treat.

Committee Recommendations (3)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated high cost immunomodulator psoriasis treatment pathway.

The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriasis High Cost immunomodulator Drug Treatment Pathway. 

The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines. The agreed process and associated documentation is saved here https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/6549

The PCN support the use of Secukinumab as a treatment option for treating moderate to severe plaque psoriasis in line NICE TA 350